NextCell Pharma AB (FRA:65G)

Germany · Delayed Price · Currency is EUR

0.0482

-0.0006 (-1.23%)

Last updated: Jan 9, 2026, 9:20 AM CET

-76.71% (1Y)

Market Cap	8.08M
Revenue (ttm)	998.29K
Net Income (ttm)	-3.17M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0482
Previous Close	0.0488
Day's Range	0.0482 - 0.0482
52-Week Range	0.0462 - 0.2940
Beta	n/a
RSI	50.23
Earnings Date	Jan 29, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2014

Employees 24

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 65G

Full Company Profile

Financial Performance

In 2025, NextCell Pharma AB's revenue was 11.06 million, a decrease of -1.90% compared to the previous year's 11.28 million. Losses were -35.14 million, -16.25% less than in 2024.

Financial numbers in SEK Financial Statements

News

There is no news available yet.